Exploring how antibody sequences work at the single-cell level using new technology
Linking antibody sequences to function at the single-cell level using nanovial technology
This study is testing a new technology that helps scientists look closely at how individual antibodies work, which could lead to quicker and better treatments for diseases like autoimmune disorders and cancer, ultimately helping patients get the right therapies faster.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10928715 on NIH RePORTER |
What this research studies
This research focuses on developing a novel technology called nanovials that allows scientists to analyze the function of antibodies at the single-cell level. By using this advanced method, researchers can sort and study individual antibody-secreting cells based on how well their antibodies bind to specific targets. This approach aims to improve the efficiency of antibody discovery, making it easier for labs to identify effective treatments for various diseases, including autoimmune disorders and cancers. Patients may benefit from faster development of new antibody therapies that are tailored to their specific conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with autoimmune diseases or cancers who may benefit from novel antibody treatments.
Not a fit: Patients who do not have conditions that can be treated with monoclonal antibodies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and personalized antibody therapies for patients.
How similar studies have performed: Other research has shown success with similar high-throughput antibody discovery technologies, indicating a promising avenue for further exploration.
Where this research is happening
Los Angeles, United States
- Partillion Bioscience Corporation — Los Angeles, United States (Active)
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.